The impact of medical insurance reimbursement on postoperative inflammation reaction in distinct cardiac surgery from a single center

Table 1 Baseline characteristics for mitral valve diseases

Characteristics	Group A (n = 235)	Group B (n = 179)	Group C (n = 101)	F/X² value	^aP value
Age, y	54.4 ± 11.2	54.3 ± 10.1	52.7 ± 10.3	0.952	0.387
Male (n, %)	65(46.4%)	65(46.1%)	38(37.6%)	2.254	0.324
Body Mass Index, kg/m²	21.9 ± 1.9	22.0 ± 2.0	22.3 ± 2.4	1.248	0.288
Current smoking (n)	18	11	13	4.042	0.133
drinking status (n)	7	9	5	1.336	0.513
inactivity status (n)	89	71	38	0.865	0.649
≥ High school Education level(n)	66	65	37	4.050	0.132
LVEF, %	56.7 ± 8.5	56.7 ± 7.7	57.2 ± 6.4	0.180	0.835
LVEDD, mm	52.4 ± 6.9	52.1 ± 6.7	51.6 ± 7.1	0.525	0.592
LAD, mm	52.4 ± 6.9	52.7 ± 6.3	53.8 ± 7.6	1.311	0.270
NYHA, I II III	33 107 95	18 86 75	10 54 37	3.143	0.534
Mitral valvuloplasty /replacement	89/146	72/107	36/65	0.600	0.741
Euroscore	2.0 ± 1.3	1.9 ± 1.3	2.0 ± 1.2	0.169	0.845

Group A: low medical coverage; Group B: medium medical coverage; Group C: high medical coverage
BMI Body Mass Index, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic dimension, LAD left atrium dimension, NYHA New York Heart Association
^ap values obtained from the repeated measures ANOVA (continuous variables) and Pearson Chi-squared tests or Fischer’s exact (dichotomous variables)

ISSN: 1472-6963